Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 16Squamous Cell Carcinoma of Head and Neck 11Esophageal Squamous Cell Carcinoma 11Esophageal Neoplasms 9Head and Neck Neoplasms 8Uterine Cervical Neoplasms 7Pancreatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Pancreatic cancer, adult 2Neoplasms 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Anal Canal 1Solid Tumors 1Solid Tumor 1Resectable Pancreatic Cancer 1Recurrence 1Penile Neoplasms 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Diseases 1NSCLC 1Meningeal Carcinomatosis 1Locally Advanced Rectal Cancer 1

Interventions

Gemcitabine 3folfirinox 2Cisplatin 2paricalcitol 1nimotuzumab 1Taxes 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Chemotherapy, Adjuvant 1Chemoradiotherapy, Adjuvant 1Albumin-Bound Paclitaxel 1Adjuvants, Immunologic 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Resectable Pancreatic Cancer × nimotuzumab × Clear all
NCT06363084 2024-04-12

A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Ruijin Hospital

Completed
64 enrolled
Gastrointestinal

Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡